SEPTEMBER 19, 2019
Biophytis to Present at 15th International Pharma Licensing Symposium in Paris. Read the Press Release
Biophytis to Present at 15th International Pharma Licensing Symposium in Paris. Read the Press Release
Biophytis has signed €24m bond funding from Negma to continue the development of its drug candidates to treat neuromuscular diseases. Read the Press Release
Shareholders Aprove All Resolutions of the Extraordinary General Meeting held on August 8, 2019. Read the Press Release
Biophytis Withdraws Registration Statement for Global Offering. Read the Press Release
Biophytis Announces Filing of Amendment to Registration Statement for Global Offering. Read the Press Release
Biophytis Announces the Launch of its Public Offering on Nasdaq. Read the Press Release
Biophytis Announces Results of 2019 Annual General Meeting of Shareholders. Read the Press Release
Biophytis Announces it Presented One Oral and One Poster Presentation at the MaculART meeting in Paris, France. Read the press release
Biophytis Enters into a Collaboration with the French Muscular Dystrophy Association (AFM-Telethon). Read the Press Release
Biophytis Expands Daniel Schneiderman’s Role to Group Chief Financial Officer. Read the Press Release